CYRXNasdaqPharmaceutical PreparationsUS GAAP · USD

Cryoport, Inc.

Cryoport, Inc. provides temperature-controlled supply chain solutions for the life sciences industry, with a particular focus on cell and gene therapies. The company combines logistics, biostorage, bioservices, cryopreservation, and cryogenic equipment manufacturing to help customers move and store sensitive biological materials under tightly regulated conditions.

Kysy yhtiöstä
Liikevaihto176milj. USD
Liikevoitto (EBIT)−36,8milj. USD
+71,9 %v/v
EBIT-marginaali−20,9%
Nettotulos78,3milj. USD
+168,2 %v/v
Vapaa kassavirta−25,0milj. USD
+25,5 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2020–2025

−200−1000100200300milj. USD2020: 79 milj. USD2020: EBIT −30 milj. USD20202021: 223 milj. USD2021: EBIT −18 milj. USD20212022: 237 milj. USD2022: EBIT −32 milj. USD20222023: 233 milj. USD2023: EBIT −101 milj. USD20232024: EBIT −131 milj. USD20242025: 176 milj. USD2025: EBIT −37 milj. USD2025176−37
LiikevaihtoLiikevoitto (EBIT)
Kysy Clarifolta: Cryoport, Inc.

Liiketoiminta

Osuus liikevaihdosta
Life Sciences Services55 %

Temperature-controlled logistics, biostorage, bioservices, and cryopreservation for life science customers.

Life Sciences Products45 %

Cryogenic systems such as freezers, dewars, and related accessories sold directly or through distributors.

Tuotteet

Raportoitu · osuus liikevaihdosta
45,2%44,4%10,4%FY2025100 %
  • Products45,2 %
  • Biologistics Solutions44,4 %
  • Biostorage Bioservices10,4 %

Lähde: 10-K FY2025, yhtiön tuotelinjoittain raportoima liikevaihto (SEC XBRL). Osuudet on laskettu näytetyistä riveistä ja ne summautuvat 100 %:iin.

Asiakkaat

Cryoport sells primarily to life sciences customers that need validated, compliant handling of sensitive biological materials. Its customer base includes biotech and pharmaceutical companies, CROs, CDMOs, central laboratories, fertility clinics, animal health companies, universities, and research facilities, with especially strong exposure to cell and gene therapy programs.

Biotechnology and pharmaceutical companies

Buy logistics, storage, and cryopreservation services for clinical and commercial biologics, especially CGT programs.

Contract research organizations and CDMOs

Use Cryoport to move trial materials and support outsourced development/manufacturing workflows.

Clinical trial sponsors

Need compliant, traceable transport for patient- or donor-derived materials across global trials.

Fertility and reproductive medicine providers

Buy cryopreservation and temperature-controlled handling for reproductive materials.

Animal health and research institutions

Purchase cryogenic systems and logistics for biological samples and research materials.

Strategia

Cryoport is focused on deepening its position in cell and gene therapy supply chains by combining digital logistics, compliance, and global infrastructure. Management is also investing in technology, geographic expansion, and new supply chain initiatives while using the CRYOPDP divestiture and DHL partnership to sharpen its international operating model.

Grow in cell and gene therapy supply chainsKeskipitkä aikaväli

CGT programs require specialized, validated logistics and create sticky customer relationships.

Digitize and integrate the operating platformKeskipitkä aikaväli

A unified digital layer improves visibility, compliance, and execution across global shipments and storage.

Rebalance the international network after CRYOPDP divestitureLyhyt aikaväli

The divestiture frees capital and allows focus on higher-value services and strategic partnerships.

Maantiede

Q1/2026

Cryoport generates most of its revenue in the Americas, with meaningful exposure to EMEA and APAC. The company operates globally and uses its international footprint to support regulated life sciences supply chains, while foreign exchange and local compliance requirements affect execution and margins.

Americas73 %
EMEA19 %
Asia Pacific8,1 %

Osuus liikevaihdosta, jonka yhtiö raportoi maantieteellisesti.

Riskit

Cryoport faces execution risk from its dependence on regulated life sciences demand, especially CGT programs that can be delayed by funding or clinical setbacks. International exposure adds FX, trade, and geopolitical risk, while the company also remains vulnerable to customer concentration, government funding disruptions, and the need to keep investing before reaching sustained profitability.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →Need for continued external capital1Foreign currency and international operating risk3U.S. federal funding disruption4
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. Need for continued external capitalVaikutus: KorkeaTodennäköisyys: Korkea

    The company expects near-term operating losses while investing in growth, which may require equity or debt financing.

    Kohdistuu: Liquidity and acquisition capacity

  2. Dependence on cell and gene therapy program activityVaikutus: Korkea

    Clinical and commercial programs can be delayed, canceled, or scaled back, reducing demand for specialized logistics and storage.

    Kohdistuu: BioLogistics and BioStorage demand

  3. Foreign currency and international operating riskVaikutus: KeskitasoTodennäköisyys: Kohtalainen

    Revenue and costs in Europe and Asia are exposed to exchange-rate swings, local regulation, and geopolitical disruption.

    Kohdistuu: EMEA and APAC operations

  4. U.S. federal funding disruptionVaikutus: KeskitasoTodennäköisyys: Kohtalainen

    Some customers rely on federal funding or agency oversight, and shutdowns can delay purchasing decisions.

    Kohdistuu: U.S. customer base

  5. Customer concentrationVaikutus: Keskitaso

    A single customer represented 10.2% of total revenue in 2025, which can create volatility if volumes change.

    Kohdistuu: Life Sciences Services segment

Kysy Clarifolta: Cryoport, Inc.

Kirjanpito

Harkinnanvaraiset erät
Revenue recognition timing

Revenue is recognized upon delivery or when control transfers, so shipping cutoffs and customer-arranged couriers affect period results.

Vaikutus: Quarterly revenue comparability

Discontinued operations

The CRYOPDP divestiture is reported separately, which changes trend analysis for continuing operations.

Vaikutus: Segment and consolidated comparability

Goodwill impairment

The company recorded prior impairments in the MVE reporting unit and still tests goodwill annually.

Vaikutus: Non-cash earnings volatility

Contingent consideration and fair value estimates

Changes in fair value can materially affect operating results and require judgment.

Vaikutus: Reported earnings and balance sheet values

Samankaltaisia listattuja yhtiöitä

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

BioLife Solutions, Inc

BLFS · Electromedical & Electrotherapeutic Apparatus

Harvard Bioscience, Inc

HBIO · Laboratory Analytical Instruments

Cryo-Cell International, Inc

CCEL · Services-Misc Health & Allied Services, NEC

Chart Industries, Inc

Fabricated Plate Work (Boiler Shops)

Callan JMB Inc

CJMB · Services-Business Services, NEC

Greenland Mines Ltd

GRMLW · Biological Products, (No Diagnostic Substances)

Päivitetty: 24.9.2026

Cryoport, Inc. (CYRX) liikevaihto, tulos ja tunnusluvut 2025 – Clarifo